Lunesta vs Dayvigo: Titration Speed and Tolerability Compared

How Each Drug Works and Why That Shapes Titration

Eszopiclone binds GABA-A receptors at the benzodiazepine site, producing sedation within 30 minutes of ingestion. Because the mechanism is a direct CNS depressant, the therapeutic window is narrow: too little and the patient stays awake, too much and next-morning impairment follows. Lemborexant blocks OX1R and OX2R orexin receptors, reducing wake-promoting signaling rather than amplifying sedation. That difference means a conservative starting dose of 5 mg is effective for most patients without the risk of over-sedation seen with higher GABA-A loading.

GABA-A Modulation (Eszopiclone)

Eszopiclone is the S-enantiomer of zopiclone and has a half-life of roughly 6 hours in healthy adults, extending to 9 hours in elderly patients. Krystal et al. (Sleep 2003, N=788) demonstrated that eszopiclone 3 mg reduced sleep-onset latency (SOL) by 15 minutes and increased total sleep time (TST) by 37 minutes versus placebo over six months of nightly use, with no evidence of tolerance at 6 months [1]. That long-duration efficacy was meaningful, but 34% of participants reported abnormal taste, the drug's most cited adverse effect.

Orexin Receptor Antagonism (Lemborexant)

Lemborexant has a half-life of 17 to 19 hours. That longer half-life can theoretically impair daytime alertness, but the drug's mechanism buffers this risk: blocking an excitatory wake signal produces gentler sedation than amplifying an inhibitory one. The FDA-approved prescribing information notes that next-morning driving performance at 10 mg was impaired on night-one testing, which is why the labeling recommends hazard warnings for the morning after the first dose at 10 mg [2].

Why Titration Differs Between the Two

Eszopiclone needs no formal titration schedule because its half-life is short enough that dose effects are largely confined to the dosing night. Lemborexant's 17 to 19-hour half-life means the drug accumulates slightly over the first several days; starting at 5 mg lets prescribers observe tolerability before committing to 10 mg. The FDA label for lemborexant states: "The recommended dose is 5 mg, taken no more than once per night, immediately before going to bed... The dose may be increased to 10 mg based on clinical response and tolerability" [2].

Titration Protocols: Step-by-Step

Eszopiclone Titration

The standard adult starting dose is 2 mg immediately before bed. Patients with hepatic impairment, age 65 or older, or concurrent CYP3A4 inhibitor use should begin at 1 mg. If 2 mg is insufficient after 7 to 14 nights, the prescriber may increase to 3 mg, the maximum approved dose. For sleep-maintenance insomnia (difficulty staying asleep rather than falling asleep), 3 mg is typically needed because the longer exposure time covers late-night awakenings [1].

The FDA label specifies that eszopiclone 3 mg "significantly" increases TST but also "may impair driving and other activities requiring full mental alertness the next day" [3]. Prescribers should counsel patients not to take eszopiclone unless they can dedicate at least 7 to 8 hours to sleep.

Lemborexant Titration

The 5-mg starting dose is effective for most adults. In SUNRISE-2 (N=949, 12-month randomized controlled trial published in Sleep Medicine 2020), lemborexant 5 mg and 10 mg both outperformed placebo for SOL and wake after sleep onset (WASO) [4]. The 10-mg dose produced larger effect sizes for WASO reduction (mean reduction 32.0 minutes vs. 25.6 minutes for 5 mg at month 1) but also higher rates of somnolence (22.1% vs. 10.2%) [4].

If 5 mg is effective, no uptitration is necessary. The prescriber should wait at least 7 days before moving to 10 mg, allowing steady-state plasma concentrations to stabilize.

Head-to-Head Titration Speed

Both drugs reach steady clinical effect within 1 to 3 nights. Eszopiclone's short half-life means it effectively "re-doses" to a new plateau each night with no meaningful accumulation; its therapeutic effect on night one is close to its effect on night 30. Lemborexant accumulates modestly over 5 to 7 days before reaching steady state, so the full sedation effect may not be apparent until the end of the first week at any given dose.

Tolerability Profiles: What Patients Actually Experience

Eszopiclone Tolerability

The metallic or bitter taste (dysgeusia) is the most distinctive complaint with eszopiclone. In the 6-month trial by Krystal et al., 34.1% of patients on 3 mg reported unpleasant taste versus 4.2% on placebo [1]. This is not a safety signal, but it is a major driver of discontinuation. Patients often describe it as a persistent metallic coating that lingers through the morning.

Other notable adverse effects from the prescribing information include:

• Headache: 21% at 3 mg vs. 17% placebo [3]
• Somnolence/dizziness: 10% at 2 mg, 8% at 3 mg [3]
• Infection (upper respiratory): 10% at 3 mg [3]
• Complex sleep behaviors (rare but serious): sleepwalking, sleep-driving, listed as a boxed warning [3]

Lemborexant Tolerability

SUNRISE-1 (JAMA Network Open 2019, N=291, 1-month randomized trial) compared lemborexant 5 mg and 10 mg directly against zolpidem tartrate extended-release 6.25 mg [5]. Lemborexant 10 mg produced significantly better WASO reduction in the second half of the night (WASO2H) compared to zolpidem ER, mean reduction 48.8 minutes vs. 43.4 minutes, P<0.001, while next-morning impairment on the Digit Symbol Substitution Test was lower for lemborexant than zolpidem ER [5].

Specific adverse event rates from SUNRISE-1 and the FDA label:

• Somnolence: 10% at 5 mg, 22% at 10 mg [2, 5]
• Headache: 6% at 5 mg, 8% at 10 mg [2]
• Dizziness: 5% at 10 mg [2]
• Sleep paralysis and hypnagogic hallucinations: rare (<2%), related to the orexin mechanism [2]
• No metallic taste reported at any rate above placebo [5]

Next-Day Impairment: The Key Safety Distinction

This is where the two drugs diverge most clinically. A 2019 study in Sleep (Moline et al., N=64) examined next-morning driving performance after a single dose of lemborexant 10 mg versus zolpidem IR 10 mg using a standardized road test [6]. Lemborexant 10 mg produced measurable lane-sway deviation at 9 hours post-dose on night one, though the effect was smaller than zolpidem IR 10 mg. By night 8 of repeated dosing, no significant driving impairment was detected with lemborexant 10 mg versus placebo [6].

Eszopiclone 3 mg, in contrast, has documented next-morning residual impairment at 8 hours post-dose in multiple studies. The American Academy of Sleep Medicine (AASM) clinical practice guideline (2017) notes that residual sedation is a class-level concern for Z-drugs taken at maximal doses, particularly in patients who drive within 8 hours of ingestion [7].

Comparative Efficacy on Sleep Architecture

Sleep architecture refers to the distribution of sleep stages across the night. This matters clinically because GABA-A agonists suppress slow-wave sleep (SWS) and REM sleep at higher doses, while orexin antagonists tend to preserve natural stage distribution.

Effect on REM and Slow-Wave Sleep

A polysomnography sub-study of SUNRISE-2 found that lemborexant 10 mg increased REM sleep percentage by a mean of 3.2 percentage points from baseline versus a 0.4-point change with placebo (P<0.05) [4]. Eszopiclone 3 mg, in analyses published alongside the Krystal 2003 data, reduced SWS by approximately 8 minutes on average versus placebo, a statistically significant decrease that was not associated with patient-reported sleep quality differences in that trial [1].

Subjective Sleep Quality Scores

Both drugs improve patient-reported outcomes. In SUNRISE-2, subjective sleep quality score (SQSQ) improved by a mean of 1.9 points (scale 1 to 5) with lemborexant 10 mg at month 6 [4]. The Krystal 2003 trial reported a mean improvement of 1.4 points on the Leeds Sleep Evaluation Questionnaire quality-of-sleep subscale with eszopiclone 3 mg at 6 months [1]. Direct cross-trial comparisons are limited by scale differences, but the magnitudes are broadly similar.

Switching from Lunesta to Dayvigo: Clinical Guidance

Switching between these two agents is a common clinical scenario, either because of metallic taste intolerance, breakthrough insomnia at the maximum eszopiclone dose, or a prescriber preference for a non-GABA mechanism in older adults. The following framework is used by the HealthRX medical team and should be reviewed with a licensed provider before implementation.

Step 1: Confirm the Reason for Switching

The rationale shapes the transition plan. Patients switching due to dysgeusia alone may do well on lemborexant 5 mg. Patients switching due to insufficient efficacy at eszopiclone 3 mg may need lemborexant 10 mg from the outset, though starting at 5 mg is still preferred to gauge tolerability.

Step 2: Taper or Stop Eszopiclone

Eszopiclone does not require a mandatory taper after short-term use (under 4 weeks) based on current evidence. For patients who have used it nightly for 3 months or longer, the American College of Physicians (ACP) recommends gradual dose reduction rather than abrupt cessation, given the potential for rebound insomnia [8]. A reasonable schedule: reduce from 3 mg to 2 mg for 7 nights, then to 1 mg for 7 nights, then stop.

Step 3: Start Lemborexant on the Night After the Last Eszopiclone Dose

No washout period is pharmacokinetically required given eszopiclone's 6-hour half-life. Begin lemborexant 5 mg. The FDA label states it should be taken within 30 minutes of going to bed and only when at least 7 hours remain before the planned waking time [2].

Step 4: Evaluate at 2 Weeks

If sleep-onset latency remains above 30 minutes or WASO exceeds 45 minutes after 14 nights on lemborexant 5 mg, uptitration to 10 mg is appropriate. A 2022 real-world analysis in the Journal of Clinical Sleep Medicine (Rosenberg et al., N=504) found that 58% of patients titrated to 10 mg reported satisfactory sleep quality at 6 weeks versus 43% who remained at 5 mg [9].

Populations That Should Not Switch Without Specialist Input

• Patients with severe hepatic impairment: lemborexant is not recommended (AUC increases 4-fold) [2]
• Patients with narcolepsy: orexin antagonists are contraindicated in narcolepsy per FDA labeling [2]
• Patients on strong CYP3A4 inhibitors (ketoconazole, clarithromycin): lemborexant exposure roughly doubles; dose should not exceed 5 mg [2]
• Patients age 65 and older: start lemborexant at 5 mg and avoid 10 mg unless benefits clearly outweigh fall-risk concerns, consistent with the American Geriatrics Society Beers Criteria 2023 recommendation that orexin antagonists are "generally acceptable" in older adults, in contrast to Z-drugs which remain on the Beers list [10]

Special Populations: Older Adults and Women

Older Adults

The 2023 American Geriatrics Society Beers Criteria explicitly lists eszopiclone as a medication to avoid in adults aged 65 and older due to increased risk of cognitive impairment, delirium, falls, and motor vehicle accidents [10]. Lemborexant does not appear on the 2023 Beers list. A pooled analysis of SUNRISE-1 and SUNRISE-2 (N=281 patients age 65 or older) found that lemborexant 5 mg and 10 mg both improved SOL and WASO with no significant increase in fall-related adverse events versus placebo [11].

Sex Differences in Metabolism

Women clear eszopiclone more slowly than men. The FDA label for Lunesta notes that maximum plasma concentration (Cmax) is approximately 20% higher in women, which is why the starting dose recommendation of 1 mg applies broadly before uptitrating [3]. No clinically significant sex difference in lemborexant pharmacokinetics was identified in population PK analyses submitted to the FDA [2].

Cost, Access, and Practical Considerations

Eszopiclone is available as a generic (since 2014) and typically costs under $25 for a 30-day supply at most U.S. Pharmacies. Lemborexant remains brand-only as of mid-2025; 30 tablets of Dayvigo 5 mg or 10 mg retail for approximately $350, $420 without insurance. Most commercial insurance plans cover lemborexant after a step-therapy requirement of at least one generic hypnotic (often zolpidem or eszopiclone) [12].

The AASM 2017 clinical practice guideline on chronic insomnia provides a conditional recommendation for both eszopiclone and lemborexant (the latter added in subsequent updates), emphasizing that drug selection should account for comorbidities, age, morning schedule demands, and patient preference, not cost alone [7].

FAQ